Research programme: nucleic acid therapeutics - Mebiopharm

Drug Profile

Research programme: nucleic acid therapeutics - Mebiopharm

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mebiopharm
  • Class Anti-infectives; Antibacterials; Antineoplastics; Nucleic acids
  • Mechanism of Action Protein serine threonine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Infections

Most Recent Events

  • 25 May 2016 Early research in Cancer in Japan (unspecified route)
  • 25 May 2016 Mebiopharm receives AMED grant from Japan Agency for Medical Research and Development for drug development in Infections
  • 25 May 2016 Early research in Infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top